Benchmarks that matter: R&D spend, margins, and success rates by the numbers

| Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète →, medical devices | ~60-70% | Physical manufacturing eats margin |

| Clinical-phase success rate (Phase 1 to approval) | ~10% | Most drug candidates fail |

| Time to develop a new drug | ~10-15 years | Why patents and cash matter so much |

A quick vocabulary reset before we go deeper:

• R&D: Research and Development, the money spent inventing and testing products.
• Gross margin: revenue minus the direct cost of making the product, divided by revenue. It ignores R&D and marketing.
• Clinical phases: the human-testing stages a drug must pass. Phase 1 (safety, small group), Phase 2 (does it work, hundreds of patients), Phase 3 (large confirmation, thousands), then regulatory review.
• FDA: US Food and Drug Administration, the US regulator. EMA: European Medicines Agency, its EU counterpart.

R&D intensity: why ~20% is the tell

Big pharma reinvests roughly a fifth of sales into R&D. Compare that to a consumer goods company at 2-3% and you understand the whole industry: value comes from discovery, not distribution.

Companies like Roche, Merck, and Novartis routinely report R&D-to-sales in the high teens to mid-twenties percent. Early-stage biotech is off the chart: a pre-revenue company spends 100%+ of its (tiny or zero) sales on R&D because it has no product yet. That is normal, not a red flag.

Sanity check in action: if a self-described "innovative pharma" company spends only 4% of sales on R&D, it is probably a generics or manufacturing business wearing an innovation costume. Generics makers (like Teva) legitimately run low R&D because they copy off-patent drugs rather than invent new ones.

Margins: drugs versus devices

The margin gap between drugs and devices is one of the most useful mental models in the sector.

A branded small-molecule pill can cost cents to manufacture and sell for dollars. That is where 70-90% gross margins come from. The expensive part already happened: the decade of R&D and trials, now sunk.

Medical devices are physical objects: a hip implant, an insulin pump, a surgical robot. They carry real bills of materials, factories, and service costs. Gross margins of 60-70% are strong performance here. Medtech leaders like Medtronic and Stryker operate in roughly this band.

Why this matters for you: never compare a device company's 65% margin unfavorably to a pharma's 85%. They are different physics. Judge each against its own peer group.

A worked calculation

A device startup projects $50M in revenue with a bill of materials of $18M and asks whether its margins are "biotech-grade."

Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → = (50, 18) / 50 = 32 / 50 = 64%.

That is a healthy, normal medtech margin. If their pitch deck claimed 85% "like a pharma company," the numbers would not support it unless they had a radically different (likely software-heavy) model. This one calculation catches the mismatch.

Success rates: the ~10% reality

Across the full journey from Phase 1 to approval, only about 1 in 10 drug candidates makes it. This is the single number that reframes how you read any drug pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète →.

Success is not evenly distributed across phases. Rough industry estimates:

• Phase 1 to Phase 2: majority pass (safety is the lower bar).
• Phase 2 to Phase 3: this is the killer, often less than half survive, because "does it actually work" is where most drugs die.
• Phase 3 to approval: a majority pass, but Phase 3 is the most expensive stage, so failures here hurt most.

Success rates also vary hugely by disease. Oncology (cancer) has historically lower success rates than, say, some infectious disease or hematology programs. The BIO/Informa "Clinical Development Success Rates" reports are a well-known free source for these breakdowns; always check the specific therapeutic area rather than using one blanket number.

Sanity check: a company with three Phase 2 assets should not be valued as if all three will reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → market. Apply attrition. If each has, say, a ~30% chance from Phase 2 onward, the expectation is closer to one product than three.

🎬 [VIDEO: "How does a drug get approved by the FDA?" - youtube.com - a short, clear walkthrough of the clinical trial phases and regulatory review]

Market size: the numbers to quote

Keep these as order-of-magnitude anchors (estimates, figures as commonly cited around 2024-2025, expect gradual growth into 2026):

• Global pharmaceutical market: on the order of $1.5 trillion in annual spending.
• United States: the largest single market, commonly estimated at roughly 40%+ of global pharma spend. This concentration is why US pricing dominates strategy conversations.
• Europe: the second major bloc, with Germany as its largest national market.
• Global medical device market: substantially smaller than pharma, commonly cited in the several-hundred-billion-dollar range (often quoted around $500-600B).

Growth rates for both sectors are typically mid-single digits annually, faster in specific hot areas like GLP-1 metabolic drugs, oncology, and AI-enabled diagnostics.

Do not over-index on any single figure. The useful skill is knowing the US is the biggest and richest market, Europe is large but more price-controlled, and devices are a smaller pie than drugs.

Acronyms you will hear in every meeting

• API: Active Pharmaceutical Ingredient, the molecule that actually does the work in a drug.
• CRO / CMO: Contract Research Organization (runs trials for you) / Contract Manufacturing Organization (makes product for you). Outsourcing partners.
• IND / NDA / BLA: Investigational New Drug application (permission to start human trials), New Drug Application and Biologics License Application (permission to sell). US/FDA terms.
• 510(k) / PMA: the two main US device approval pathways. A 510(k) clears a device by showing it is similar to one already on the market (faster, lower risk). PMA (Premarket Approval) is the strict pathway for high-risk devices, much closer to a full drug-style review.
• CE mark: the marking that lets a device be sold in Europe, now governed by the EU MDR (Medical Device Regulation), which tightened requirements considerably.
• COGS: Cost of Goods Sold, the direct manufacturing cost behind gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète →.

Knowing that a device took the 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) route versus PMA instantly tells you something about its risk class and how much clinical evidence stood behind it.

The due-diligence checklist

When you assess a biotech or medtech company, run these practical checks:

1. Match R&D intensity to the story. Innovator claims should come with double-digit R&D-to-sales. Low R&D means a generics or manufacturing model.

2. Judge margins against the right peer group. 65% is great for devices, mediocre for branded drugs.

3. Apply attrition to the pipeline. Discount Phase 2 assets heavily. Ask which therapeutic area, since cancer odds differ from others.

4. Check the patent cliff. When do the key patents expire? A blockbuster drug losing exclusivity can lose most of its revenue to generics within a year or two. Ask: what replaces that revenue?

5. Confirm the regulatory pathway and status. Is it FDA-approved, EMA-approved, 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →)-cleared, CE-marked? "In discussions with regulators" is not approval.

6. Follow the cash. Pre-revenue biotech burns cash for years. How many months of runway remain before the next raise?

None of this is investment advice. It is the fluency that lets you ask the right question in the room.

Key Takeaways

• Memorize the five anchors: ~20% R&D-to-sales, 70-90% drug margins, 60-70% device margins, ~10% clinical success, 10-15 years to market.
• Never compare drug and device margins head-to-head. Different physics, different peer groups.
• The Phase 2 to Phase 3 transition is where most drugs die. Discount early pipelines accordingly, and always check the therapeutic area.
• The US is the largest and highest-priced pharma market (~40%+ of global spend, estimate); Europe is large but more price-controlled.
• Always verify the regulatory pathway (IND, NDA, BLA, 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →), PMA, CE mark) and the cash runway. Claims are not approvals.